The Statistical Foundation Beneath Peptide Research Claims
Every preclinical claim about a peptide compound—its receptor binding affinity, its potency in a cell-based assay, its efficacy in an animal model—rests on a statistical argument. That argument, in the vast majority of published studies, centres on a single number: the p-value. When that number falls below 0.05, findings are reported as statistically significant. When it does not, results are frequently left unpublished or quietly set aside.
This convention, inherited from early twentieth-century frequentist statistics, was never intended to serve as a binary threshold for scientific truth. Yet in peptide pharmacology, as across the biomedical sciences, it has functioned as precisely that—with consequences for reproducibility, resource allocation, and the credibility of the preclinical literature [1].
This article examines how p-values are commonly misapplied in peptide research, what corrections and alternatives exist, and how researchers can read the preclinical literature with greater statistical literacy.
What a P-Value Actually Measures
A p-value answers a narrow and specific question: given that the null hypothesis is true (i.e., that there is no real effect), how probable is it that the observed data—or data more extreme—would arise by chance alone? A p-value of 0.03 means there is a 3% probability of observing the measured result if the null hypothesis holds.
What a p-value does not measure is equally important to understand. It does not indicate the probability that the null hypothesis is true. It does not reflect the size or biological importance of an effect. It does not confirm that a result will replicate [8]. These distinctions matter enormously when interpreting a peptide binding assay that reports, for example, a statistically significant difference in IC₅₀ values between two analogues.
The American Statistical Association addressed these misconceptions formally in 2016, issuing a statement that explicitly cautioned against using p < 0.05 as the sole criterion for scientific conclusions [3]. That guidance has been slow to penetrate the peptide pharmacology literature, where the threshold retains near-universal authority.
Statistical Significance Is Not Biological Meaningfulness
One of the most consequential conflations in preclinical research is treating statistical significance as equivalent to biological relevance. The two concepts are related but distinct, and in peptide studies the gap between them can be substantial.
Consider a dose-response study comparing two peptide agonists at a G protein-coupled receptor. With a sufficiently large sample size, even a trivially small difference in EC₅₀—say, 0.3 nM versus 0.4 nM—may reach statistical significance. Whether that difference has any meaningful pharmacological consequence depends on the therapeutic window, receptor reserve, and downstream signalling context, none of which a p-value addresses.
Conversely, a study with a small sample size may fail to detect a genuinely important difference in binding kinetics because it lacks the statistical power to do so. The p-value in that case reflects the study's design limitations, not the underlying biology. Biological meaningfulness requires effect size estimation and contextual interpretation—tools that p-values alone cannot provide [4].
The Multiple Comparisons Problem in Peptide Screening
Modern peptide research frequently involves testing a single compound—or a library of analogues—across multiple receptor subtypes, tissue preparations, timepoints, or dose levels simultaneously. Each additional statistical test performed on the same dataset increases the probability that at least one result will appear significant purely by chance.
This is the multiple comparisons problem. If twenty independent statistical tests are conducted at a significance threshold of p < 0.05, one false positive is expected on average even when no true effects exist. In a receptor profiling study testing a novel peptide across thirty receptor subtypes, the probability of at least one spurious significant result approaches 79% under the null hypothesis.
Three correction approaches are widely used to address this problem. The Bonferroni correction divides the significance threshold by the number of comparisons, making it more conservative but prone to false negatives when many tests are conducted. The Holm-Bonferroni method applies a sequential adjustment that is less conservative while maintaining strong control of the family-wise error rate. The Benjamini-Hochberg procedure controls the false discovery rate (FDR)—the expected proportion of significant results that are false positives—rather than the probability of any single false positive, making it better suited to high-throughput peptide screening contexts [2].
When reading a peptide pharmacology paper that reports significant effects across multiple endpoints without mentioning any correction for multiple comparisons, that omission warrants careful scrutiny. The absence of correction does not invalidate the findings, but it substantially increases the prior probability that some reported effects are artefactual.
P-Hacking and Selective Reporting: Recognising the Red Flags
P-hacking refers to the practice—sometimes deliberate, often unconscious—of manipulating analytical choices until a p-value crosses the significance threshold. These choices include when to stop collecting data, which covariates to include in a model, how to define outcome measures, and which subgroups to analyse. Each decision point represents what statisticians call a researcher degree of freedom [7].
In peptide pharmacology, p-hacking can manifest in several recognisable patterns. A study may report that a peptide significantly reduced a biomarker at one timepoint but not others, without a pre-specified rationale for selecting that timepoint. A binding assay may report significance for one receptor subtype from a panel of ten, with the remaining nine results absent from the results section. An in vivo efficacy study may switch its primary outcome from body weight to food intake after data collection, reporting the measure that happened to reach significance.
Selective reporting of positive results—sometimes called publication bias—compounds the problem at the literature level. When negative results remain unpublished, the available evidence base for any given peptide becomes systematically skewed toward false positives [1]. Meta-analyses and systematic reviews of peptide candidates are therefore working with a distorted sample of the true experimental record.
Red flags to watch for in published studies include: post-hoc analyses presented without acknowledgement that they were exploratory; outcome measures that differ from those stated in a registered protocol; unusually clean dose-response curves with no variance at any point; and results sections that report only the subset of endpoints that reached significance.
Underpowered Studies and the Inflation of Effect Sizes
Statistical power is the probability that a study will detect a true effect of a given magnitude. A study with 80% power has a 20% chance of missing a real effect—a type II error. In practice, many preclinical peptide studies, particularly those using small rodent cohorts of six to ten animals per group, operate at substantially lower power than this standard.
Underpowered studies create two interrelated problems. First, they produce high rates of false negatives, meaning genuine biological effects go undetected. Second, and less intuitively, the effect sizes reported by underpowered studies that do reach significance tend to be inflated. This occurs because only the largest chance fluctuations in an underpowered study will cross the significance threshold; smaller, more representative estimates of the true effect will not [6].
The practical consequence for peptide research is that an in vivo efficacy study reporting a dramatic effect size—say, a 60% reduction in a disease marker—from a group of eight animals may be reporting a statistical artefact rather than a reliable biological signal. When that study is used to justify advancing a peptide candidate toward clinical development, the inflated effect size creates unrealistic expectations that clinical trials are unlikely to meet.
Power calculations should be conducted before data collection, not after. When a published study does not report a pre-study power analysis, readers should treat the reported effect sizes with proportionate scepticism.
Confidence Intervals and Effect Sizes: More Informative Alternatives
Confidence intervals and effect sizes provide information that p-values systematically withhold. A 95% confidence interval around a binding affinity estimate communicates both the direction and the precision of the measured effect. A wide confidence interval—for example, a Ki of 12 nM with a 95% CI of 2–70 nM—signals that the estimate is imprecise and that the study was likely underpowered, regardless of whether the associated p-value is significant.
Effect sizes—such as Cohen's d for continuous outcomes or the fold-change in receptor occupancy between conditions—quantify the magnitude of a difference in standardised units. They allow comparisons across studies using different assay formats and scales, enabling a more meaningful synthesis of the peptide literature than p-value tallies permit [4].
The transition toward confidence interval and effect size reporting has been advocated by statisticians and journal editors for decades, and some pharmacology journals now require their inclusion. When evaluating a peptide study, prioritising these measures over the binary significant/non-significant classification leads to more nuanced and accurate interpretation.
Interpreting Non-Significant Results: Absence of Evidence
A non-significant p-value is frequently interpreted as evidence that a peptide has no effect. This interpretation is incorrect and carries its own risks. A non-significant result means only that the study did not produce sufficient evidence to reject the null hypothesis under the chosen threshold—it does not confirm that the null hypothesis is true.
The distinction matters practically. A cell-based potency assay that fails to detect a difference between a peptide analogue and a vehicle control may have been too small to detect a modest but real effect. Concluding from that result that the analogue is inactive could prematurely terminate a promising line of investigation.
Equivalence testing—a statistical framework that asks whether an effect is small enough to be considered negligible—provides a more rigorous basis for null conclusions than a non-significant p-value alone. When a study genuinely intends to demonstrate that two peptides have equivalent potency, equivalence testing with pre-specified margins is the appropriate analytical tool [3].
The Reproducibility Context: From Preclinical Findings to Clinical Failure
The reproducibility crisis in biomedical research has been extensively documented, and peptide pharmacology has not been immune to it. A substantial proportion of preclinical findings that informed clinical development programmes have failed to replicate when subjected to independent testing, and the statistical practices described in this article are among the structural contributors to that failure rate [1].
When a peptide candidate advances to clinical trials on the basis of preclinical data that were underpowered, uncorrected for multiple comparisons, or subject to selective reporting, the clinical programme is built on an uncertain foundation. The effect sizes that justified the trial may be inflated; the receptor selectivity profile may reflect false positives; the dose-response relationship may not generalise from the animal model to humans.
Addressing these issues requires changes at multiple levels: in how individual researchers design and analyse studies, in how journals review and report statistical methods, and in how the field collectively treats negative and null results. Preregistration of study protocols—committing to primary outcomes, sample sizes, and analytical approaches before data collection—is one structural intervention that reduces the scope for post-hoc analytical flexibility [7].
A Framework for Evaluating Statistical Reporting in Peptide Studies
When reading a preclinical peptide study, several questions can guide a more rigorous assessment of its statistical claims.
Was a power analysis reported, and does the sample size align with it? Studies that report a power analysis but use sample sizes inconsistent with it, or that report no power analysis at all, warrant closer scrutiny of their effect size estimates.
How many statistical tests were conducted, and were corrections applied? A results section reporting ten significant findings from fifty tests without multiple comparisons correction is statistically suspect.
Are confidence intervals reported alongside p-values? Confidence intervals communicate precision; their absence limits the interpretability of any reported effect.
Do the reported outcomes match those described in the methods section? Discrepancies between pre-specified and reported outcomes are a signal of potential outcome switching.
Are null or negative results reported? A study that tests a peptide across multiple endpoints and reports only the significant ones is presenting an incomplete picture.
Is the effect size biologically plausible given the assay system and the compound class? Unusually large effects in small samples should prompt additional verification rather than immediate acceptance.
These questions do not presuppose bad faith on the part of researchers. Many statistical errors in the preclinical literature arise from training gaps rather than deliberate manipulation. Applying this framework is an act of critical engagement with the literature, not an accusation.
Conclusion
The p-value is a useful but limited statistical tool. Its limitations become consequential when it is treated as the primary arbiter of scientific truth in peptide preclinical research—a role it was never designed to fill. Understanding the multiple comparisons problem, the effects of underpowered designs, the mechanics of selective reporting, and the superior information content of confidence intervals and effect sizes equips researchers to read the preclinical literature with greater precision and to design studies that generate more reliable evidence.
The goal is not to dismiss the existing literature but to engage with it more carefully—distinguishing findings that rest on robust statistical foundations from those that require independent replication before informing further research decisions. In a field where preclinical-to-clinical translation rates remain a persistent challenge, that distinction carries real consequences.